BioMarin Pharmaceutical Inc. [NASDAQ: BMRN] stock went on an upward path that rose over 1.86% on Friday, amounting to a one-week price increase of more than 0.80%. The company report on July 2, 2021 that BioMarin Announces 12 Presentations at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress.
Findings to be Presented from Ongoing Studies of Valoctocogene Roxaparvovec Represent Largest and Longest Development Program for any Gene Therapy in Hemophilia A.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced three oral presentations and nine poster presentations related to valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress being held July 17-21, 2021. Notably, these presentations will include highlights from the Phase 3 GENEr8-1 trial, the largest gene therapy trial in Hemophilia A, and five years of clinical follow-up from the Phase 1/2 study, both of which continue to demonstrate prolonged hemostatic efficacy without the need for other treatment for hemophilia A.
Over the last 12 months, BMRN stock dropped by -32.58%. The one-year BioMarin Pharmaceutical Inc. stock forecast points to a potential upside of 20.2. The average equity rating for BMRN stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $15.33 billion, with 181.77 million shares outstanding and 181.71 million shares in the current float. Compared to the average trading volume of 914.51K shares, BMRN stock reached a trading volume of 947537 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on BioMarin Pharmaceutical Inc. [BMRN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMRN shares is $107.11 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMRN stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Robert W. Baird have made an estimate for BioMarin Pharmaceutical Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 04, 2021. While these analysts kept the previous recommendation, Credit Suisse raised their target price to Outperform. The new note on the price target was released on April 26, 2021, representing the official price target for BioMarin Pharmaceutical Inc. stock. On March 01, 2021, analysts increased their price target for BMRN shares from 90 to 100.
The Average True Range (ATR) for BioMarin Pharmaceutical Inc. is set at 1.74, with the Price to Sales ratio for BMRN stock in the period of the last 12 months amounting to 8.31. The Price to Book ratio for the last quarter was 3.73, with the Price to Cash per share for the same quarter was set at 6.06. Price to Free Cash Flow for BMRN in the course of the last twelve months was 133.57 with Quick ratio for the last quarter at 3.70.
BMRN Stock Performance Analysis:
BioMarin Pharmaceutical Inc. [BMRN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.80. With this latest performance, BMRN shares gained by 10.48% in over the last four-week period, additionally sinking by -2.53% over the last 6 months – not to mention a drop of -32.58% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMRN stock in for the last two-week period is set at 66.99, with the RSI for the last a single of trading hit 70.22, and the three-weeks RSI is set at 64.02 for BioMarin Pharmaceutical Inc. [BMRN]. The present Moving Average for the last 50 days of trading for this stock 79.72, while it was recorded at 84.14 for the last single week of trading, and 79.99 for the last 200 days.
Insight into BioMarin Pharmaceutical Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and BioMarin Pharmaceutical Inc. [BMRN] shares currently have an operating margin of -5.69 and a Gross Margin at +68.17. BioMarin Pharmaceutical Inc.’s Net Margin is presently recorded at +46.63.
Return on Total Capital for BMRN is now -2.26, given the latest momentum, and Return on Invested Capital for the company is 19.34. Return on Equity for this stock inclined to 23.77, with Return on Assets sitting at 16.30. When it comes to the capital structure of this company, BioMarin Pharmaceutical Inc. [BMRN] has a Total Debt to Total Equity ratio set at 27.55. Additionally, BMRN Total Debt to Total Capital is recorded at 21.60, with Total Debt to Total Assets ending up at 19.35. Long-Term Debt to Equity for the company is recorded at 27.27, with the Long-Term Debt to Total Capital now at 21.38.
Reflecting on the efficiency of the workforce at the company, BioMarin Pharmaceutical Inc. [BMRN] managed to generate an average of $280,843 per employee. Receivables Turnover for the company is 4.46 with a Total Asset Turnover recorded at a value of 0.35.BioMarin Pharmaceutical Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.70 and a Current Ratio set at 5.30.
BMRN Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMRN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioMarin Pharmaceutical Inc. go to 32.16%.
BioMarin Pharmaceutical Inc. [BMRN] Insider Position Details
There are presently around $15,179 million, or 98.30% of BMRN stock, in the hands of institutional investors. The top three institutional holders of BMRN stocks are: CAPITAL RESEARCH GLOBAL INVESTORS with ownership of 22,076,365, which is approximately -0.012% of the company’s market cap and around 0.50% of the total institutional ownership; PRIMECAP MANAGEMENT CO/CA/, holding 18,157,794 shares of the stock with an approximate value of $1.55 billion in BMRN stocks shares; and VANGUARD GROUP INC, currently with $1.4 billion in BMRN stock with ownership of nearly -0.094% of the company’s market capitalization.
Positions in BioMarin Pharmaceutical Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 251 institutional holders increased their position in BioMarin Pharmaceutical Inc. [NASDAQ:BMRN] by around 11,568,991 shares. Additionally, 266 investors decreased positions by around 15,755,757 shares, while 80 investors held positions by with 150,265,897 shares. The mentioned changes placed institutional holdings at 177,590,645 shares, according to the latest SEC report filing. BMRN stock had 75 new institutional investments in for a total of 1,458,996 shares, while 82 institutional investors sold positions of 3,919,281 shares during the same period.